Tandem Diabetes Care (TNDM) Cost of Revenue (2013 - 2026)

Tandem Diabetes Care's Cost of Revenue history runs 14 years deep, the most recent figure standing at $110.4 million for Q1 2026.

• Quarterly Cost of Revenue fell 4.81% year-over-year to $110.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $463.1 million (down 1.38% YoY) and the FY2025 annual result came in at $468.7 million, up 4.02% from the prior year.
• Cost of Revenue was $110.4 million for Q1 2026 at Tandem Diabetes Care, down from $122.9 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $125.2 million in Q4 2024 and bottomed at $84.8 million in Q1 2022.
• A 5-year average of $105.8 million and a median of $105.0 million in 2022 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue advanced 25.19% — and 2026, when it decreased 4.81%.
• Tandem Diabetes Care's Cost of Revenue stood at $105.0 million in 2022, then decreased by 1.41% to $103.5 million in 2023, then advanced by 20.96% to $125.2 million in 2024, then fell by 1.81% to $122.9 million in 2025, then declined by 10.16% to $110.4 million in 2026.
• Business Quant data shows TNDM's Cost of Revenue at $110.4 million in Q1 2026, $122.9 million in Q4 2025, and $115.0 million in Q3 2025.